Processa Pharmaceuticals’ (NASDAQ: PCSA) shares skyrocketed by over 260% from their October lows of $0.18 per share. Shares peaked at $0.65 on November 14th and more recently has consolidated around $0.43. The reason for this surge was not immediately clear given the lack of material events. However upon digging deeper, we’ve uncovered a very interesting […]
In a newly unsealed deposition, a former Express Scripts executive (unintentionally) reveals how hard his colleagues were undermining his ‘mission’ to cut drug prices.
GT Biopharma (GTBP) Appoints Charles J. Casamento to its Board streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
2022 saw key trends emerge in qui tam law. More than $2.2 billion were collected from settlements and judgements in civil cases alleging fraud against the government. Looking ahead, a Supreme Court decision looms, as SCOTUS considers DOJ standard of dismissal in False Claims Act cases.
Settlements and judgments under the False Claims Act exceeded $2.2 billion in the fiscal year that ended on September 30, more than $1.7 billion of which pertained to matters that involved the healthcare industry – including drug and medical device manufacturers, durable medical equipment, home health and managed care providers, hospitals, pharmacies, hospice organizations and